NOME portfolio company Droplet IV has successfully closed a funding round, raising DKK 13 million (approximately USD 2 million) to support regulatory progress and prepare for commercial launch in both the EU and US markets.
Droplet IV is developing an automated medical device designed to flush intravenous (IV) lines between drug administrations. This process, typically done manually by nurses, is essential to ensure full delivery of prescribed medication and to reduce the risk of drug interactions. Automating it can improve dosing accuracy, reduce clinical workload, and minimise medicine waste—creating clear value for both patients and healthcare providers.
The round attracted investment from a group of experienced healthcare professionals and medtech investors, including individuals with operational backgrounds in international medical device companies. The capital will enable the company to accelerate product development, navigate regulatory pathways, and establish commercial readiness ahead of its planned launch in 2026.
Founded in 2022, Droplet IV has been part of NOME since 2024.